APPLICATION
ANDA205722
TYPE
ANDA
ORIGINAL APPROVAL
2019-10-18
LATEST ACTION
2023-11-28
ROUTE
INTRAVENOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Discontinued
Products
TIGECYCLINEDiscontinued
TIGECYCLINE 50MG/VIAL · POWDER · INTRAVENOUS
Approval history
2023-11-28Labeling · Supplement 3 · standardAP
2023-11-28Labeling · Supplement 4 · standardAP
2019-10-18UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.